Furthermore, although less prevalent in MM, mutations in ATM or ATR genes were lately reported to be associated with a negative impact on survival of MM patients enrolled onto the NCRI Myeloma XI Trial, in which the inability to deliver an effective apoptotic response to DNA damage represented the most significantly prognostic mutational marker [5]. This evidence concerns the gene ATR and plasma cell myeloma.